---
slug: ss-31
title: "ss 31"
kind: standard
status: published
hash: 590e94935f2d36fc6f12b802f1eff10707c1eb280a4a0d71675ce72fc33e5ee0
created: 2026-06-29T16:50:17.514Z
updated: 2026-10-08T11:50:02.398Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# ss 31

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T16:50:18.283Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential](https://pubmed.ncbi.nlm.nih.gov/39940712/) — “Elamipretide (SS-31, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide designed to treat mitochondrial dysfunction via binding to cardiolipin.” (sha256 c5e24d52fb7d1318)
2. [SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis](https://pubmed.ncbi.nlm.nih.gov/40299935/) — “The mitochondria-targeting drug SS-31 exhibited potential in mitigating bleomycin-induced pulmonary fibrosis, improving mitochondrial function.” (sha256 83ceb7bb7645b8f5)
3. [Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval](https://pubmed.ncbi.nlm.nih.gov/41260682/) — “On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide, the first therapy directly targeting the mitochondrial etiology of BTHS.” (sha256 ac100c72e3c4a46f)
4. [Elamipretide (SS-31) Promotes Recovery by Preserving Mitochondrial Bioenergetics and Neural Remodeling after Spinal Cord Injury](https://pubmed.ncbi.nlm.nih.gov/42082001/) — “Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects. Here, we investigated whether SS-31 improves functional outcomes after contusive SCI.” (sha256 6ee5b65f6b54ae50)